Cargando…

Paroxetine in the treatment of recurrent brief depressive disorder

Recurrent brief depressive disorder is now a well-recognized type of depressive disorder. However, there is still no clear evidence base for its treatment. The efficacy of several drugs including antidepressants and mood stabilizers in this disorder has been controversial. Methodological limitations...

Descripción completa

Detalles Bibliográficos
Autores principales: Prakash, Sathya, Mandal, Piyali, Sagar, Rajesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3826008/
https://www.ncbi.nlm.nih.gov/pubmed/24250209
http://dx.doi.org/10.4103/0976-500X.119718
_version_ 1782290864843784192
author Prakash, Sathya
Mandal, Piyali
Sagar, Rajesh
author_facet Prakash, Sathya
Mandal, Piyali
Sagar, Rajesh
author_sort Prakash, Sathya
collection PubMed
description Recurrent brief depressive disorder is now a well-recognized type of depressive disorder. However, there is still no clear evidence base for its treatment. The efficacy of several drugs including antidepressants and mood stabilizers in this disorder has been controversial. Methodological limitations need to be considered when interpreting the results of studies on efficacy of drugs in this disorder. We report a case of recurrent brief depressive disorder that responded dramatically to paroxetine. However, there is a need for larger, methodologically sound, double-blind, placebo-controlled studies.
format Online
Article
Text
id pubmed-3826008
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-38260082013-11-18 Paroxetine in the treatment of recurrent brief depressive disorder Prakash, Sathya Mandal, Piyali Sagar, Rajesh J Pharmacol Pharmacother Case Report Recurrent brief depressive disorder is now a well-recognized type of depressive disorder. However, there is still no clear evidence base for its treatment. The efficacy of several drugs including antidepressants and mood stabilizers in this disorder has been controversial. Methodological limitations need to be considered when interpreting the results of studies on efficacy of drugs in this disorder. We report a case of recurrent brief depressive disorder that responded dramatically to paroxetine. However, there is a need for larger, methodologically sound, double-blind, placebo-controlled studies. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3826008/ /pubmed/24250209 http://dx.doi.org/10.4103/0976-500X.119718 Text en Copyright: © Journal of Pharmacology and Pharmacotherapeutics http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Prakash, Sathya
Mandal, Piyali
Sagar, Rajesh
Paroxetine in the treatment of recurrent brief depressive disorder
title Paroxetine in the treatment of recurrent brief depressive disorder
title_full Paroxetine in the treatment of recurrent brief depressive disorder
title_fullStr Paroxetine in the treatment of recurrent brief depressive disorder
title_full_unstemmed Paroxetine in the treatment of recurrent brief depressive disorder
title_short Paroxetine in the treatment of recurrent brief depressive disorder
title_sort paroxetine in the treatment of recurrent brief depressive disorder
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3826008/
https://www.ncbi.nlm.nih.gov/pubmed/24250209
http://dx.doi.org/10.4103/0976-500X.119718
work_keys_str_mv AT prakashsathya paroxetineinthetreatmentofrecurrentbriefdepressivedisorder
AT mandalpiyali paroxetineinthetreatmentofrecurrentbriefdepressivedisorder
AT sagarrajesh paroxetineinthetreatmentofrecurrentbriefdepressivedisorder